{"filing":{"accession_number":"0001193125-26-272582","cik":"0001831915","ticker":"CTKB","company_name":"Cytek Biosciences, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"d107901d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526272582/d107901d8k.htm"},"events":[{"id":11302,"run_id":9920,"accession_number":"0001193125-26-272582","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Cytek Biosciences' June 10, 2026 annual meeting. The filing reports voting outcomes on three matters: election of Class II directors (Vera Imper, Glenn P. Muir, and Ming Yan), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All three matters passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely on to assess board composition and management accountability.","company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7859,"accession_number":"0001193125-26-272582","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Cytek Biosciences' June 10, 2026 annual meeting. The filing reports voting outcomes on three matters: election of Class II directors (Vera Imper, Glenn P. Muir, and Ming Yan), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All three matters passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely on to assess board composition and management accountability.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:09:02.728379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7859,"accession_number":"0001193125-26-272582","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Cytek Biosciences' June 10, 2026 annual meeting. The filing reports voting outcomes on three matters: election of Class II directors (Vera Imper, Glenn P. Muir, and Ming Yan), advisory approval of executive compensation, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All three matters passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely on to assess board composition and management accountability.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:09:02.728379+00:00","company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","filing_date":"2026-06-16"}]}